Nanodrug delivery systems for metabolic chronic liver diseases: advances and perspectives - Supplementary information

Nanomedicines are revolutionizing healthcare as recently demonstrated by the Pfizer/BioNTech and
Moderna COVID-2019 vaccines, with billions of doses administered worldwide in a safe manner.
Nonalcoholic fatty liver disease is the most common noncommunicable chronic liver disease, posing a
major growing challenge to global public health. However, due to unmet diagnostic and therapeutic
needs, there is great interest in the development of novel translational approaches. Nanoparticle-based
approaches offer novel opportunities for efficient and specific drug delivery to liver cells, as a step
toward precision medicines. In this review, the authors highlight recent advances in nanomedicines for
the generation of novel diagnostic and therapeutic tools for nonalcoholic fatty liver disease and related
liver diseases.